A Phase 2 interventional study of MEDI-551 2 mg/kg and Rituximab in Diffuse Large B-Cell Lymphoma, sponsored by MedImmune LLC. Completed at 83 sites in 11 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-03-12.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca — 1 open to participants now, 3 under way, 1 of them phase 3. Lymphoma, Large B-Cell, Diffuse · AstraZeneca.
Among the 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2012, is one of 3 in phase 2, and was the 1st registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →1 of the 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca is open now, in 5 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Brazil, Puerto Rico and 2 more countries
Ages 65–99
By country, each count listing its studies:
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 4 · Phase 3 1
First in 2011; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 187 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 67 across the 11 interventional studies, 600 across the 1 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
1 of the studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The overall purpose of the study is to determine if MEDI-551, when used in combination with salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) or Dexamethasone-cytarabine (DHAP) in patients with relapsed or refractory DLBCL who are eligible for Autologous Stem Cell Transplant (ASCT), has superior efficacy compared to rituximab in the same population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Rituximab in combination with ifosfamide + carboplatin + etoposide (ICE) or dexamethasone + cisplatin + cytarabine (DHAP) for 3 cycles (21-day cycles) and will followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). Rituximab (375 mg/m\^2) will be administered intravenous (IV) on 2 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of rituximab, IV infusion of ICE as: ifosfamide 5 g/ m\^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m\^2 on Days 1, 2, and 3 in 21-day cycles. After completion of rituximab, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m\^2 continuously for 24 hours on Day 1; cytarabine 2 g/m\^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
Drug: Rituximab · Drug: ICE · Drug: DHAP · Procedure: Autologous Stem Cell Transplant (ASCT)
Participants will receive MEDI-551 (2 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (2 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m\^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m\^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m\^2 continuously for 24 hours on Day 1; cytarabine 2 g/m\^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
Drug: MEDI-551 2 mg/kg · Drug: ICE · Drug: DHAP · Procedure: Autologous Stem Cell Transplant (ASCT)
Participants will receive MEDI-551 (4 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (4 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m\^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m\^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m\^2 continuously for 24 hours on Day 1; cytarabine 2 g/m\^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
Drug: ICE · Drug: DHAP · Procedure: Autologous Stem Cell Transplant (ASCT) · Drug: MEDI-551 4 mg/kg
Drug page: Inebilizumab
MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
Also known as: Inebilizumab
Rituximab at 375 mg/m2 will be administered via IV infusion 2 days before the start of Cycle 1 and on Day 1 of each cycle. The infusion time for rituximab will be 50 400 mg/hr, depending on subject's tolerance. Subjects will receive 3 cycles of Rituximab with Ice (R ICE) or Rituximab with DHAP (R-DHAP) unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
Also known as: Rituxan; MabThera
ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min \[800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.
Drug pages: Dexamethasone · Cytarabine · Cisplatin
DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
Subjects who achieve CR or PR will undergo stem cell harvest and autologous stem cell transplantation (ASCT) following standard institutional protocols.
Drug page: Inebilizumab
MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
Also known as: Inebilizumab
Objective Response Rate (ORR)
Objective Response Rate is defined as the proportion of participants with a best response of complete response (CR) or partial response (PR) according to the International Working Group criteria. CR is defined as disappearance of all evidence of disease. PR is defined as 50 percent (%) decrease in the sum of the product of the perpendicular diameters (SPD) of up to 6 largest dominant nodal masses and greater than or equal to (\>=) 50% decrease in SPD of spleen/liver nodules.
Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Progression-Free Survival (PFS)
Progression-free survival (PFS) is defined as the time from randomization until the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first according to the International Working Group criteria. PD is defined as appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \>50% increase from nadir in the SPD of any previous lesions. PFS (months) = (Date of PD/death or censoring - Date of randomization + 1) / (365.25/12).
Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Event-Free Survival (EFS)
Event-Free Survival (EFS) is defined as the time from randomization until the first documentation of EFS events which include PD, initiation of alternative antitumor treatment or death due to any cause, whichever occurs first according to the International Working Group criteria. PD is defined as appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \>50% increase from nadir in the SPD of any previous lesions. EFS (months) = (Date of EFS or censoring - Date of randomization + 1) / (365.25/12).
Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Overall Survival (OS)
Overall survival is defined as the time from randomization until death due to any cause according to the International Working Group criteria. OS (months) = (Date of death or censoring - Date of randomization + 1) / (365.25/12).
Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Time to Progression (TTP)
Time to Progression (TTP) is defined as the time from randomization until the first documentation of PD according to the International Working Group criteria. PD is defined as appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \>50% increase from nadir in the SPD of any previous lesions. TTP (months) = (Date of PD or censoring - Date of randomization + 1) / (365.25/12).
Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Time to Response (TTR)
Time to response (TTR) is defined as the time from randomization until the first documentation of disease response according to the International Working Group criteria. Only participants who have achieved objective response (confirmed CR or confirmed PR) assessed by investigator were evaluated for TTR. CR is defined as disappearance of all evidence of disease. PR is defined as 50% decrease in the SPD of up to 6 largest dominant nodal masses and \>= 50% decrease in SPD of spleen/liver nodules. TTR (months) = (Date of first disease response - Date of randomization + 1) / (365.25/12).
Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Duration of Response (DR)
Duration of Response (DR) is defined as time from start of first documented objective response (confirmed CR or confirmed PR) to first documented PD according to the International Working Group criteria. CR is defined as disappearance of all evidence of disease. PR is defined as 50% decrease in the SPD of up to 6 largest dominant nodal masses and \>= 50% decrease in SPD of spleen/liver nodules. PD: appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \> 50% increase from nadir in the SPD of any previous lesions. Only participants who have achieved objective response assessed by investigator were evaluated. DR calculated as (months) = (Date of PD or censoring - Date of first disease response + 1)/ (365.25/12).
Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Number of Participants With Best Overall Response Assessed by Blinded Independent Central Review (BICR)
The best overall response was calculated, based upon the disease assessments recorded during the study visits, and summarized with the number of participants for the following categories: CR, PR, stable disease (SD), PD, and unknown. Responses were assessed according to the International Working Group criteria. CR: disappearance of all evidence of disease; PR: 50% decrease in the SPD of up to 6 largest dominant nodal masses and \>= 50% decrease in SPD of spleen/liver nodules; PD: appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \>50% increase from nadir in the SPD of any previous lesions; SD: failure to attain CR/PR or PD.
Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Acceptable Dose of MEDI-551
Acceptable dose for MEDI-551 was evaluated based on the benefit-risk analysis.
Time frame: After the administration of the first dose of MEDI-551 (7 days before the Cycle 1) to last dose of MEDI-551 (Cycle 3 Day 1) (each cycle of 21 days)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An Adverse Event (AE) is any unfavourable and unintended signs, symptoms, or diseases temporally associated with use of study drug, whether or not considered related to study drug. Serious adverse event (SAE) is any AE that resulted in death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, life-threatening, a congenital anomaly/birth defect, or an important medical event. TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug, up to 90 days after the end of treatment (EOT).
Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Hematology/Coagulation Laboratory Results
An abnormal laboratory finding that was judged by the investigator to be clinically significant was reported as an AE. TEAEs were defined as events present at baseline that worsened in intensity after administration of MEDI-551, or events absent at baseline that emerged after administration of MEDI-551, for the period extending to 90 days after the end of study treatment (EOT).
Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Chemistry Laboratory Results (Include Urinalysis)
An abnormal laboratory findings that was judged by the investigator to be clinically significant was reported as an AE. TEAEs were defined as events present at baseline that worsened in intensity after administration of MEDI-551, or events absent at baseline that emerged after administration of MEDI-551, for the period extending to 90 days after the end of study treatment.
Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Vital Signs and ECG Abnormalities
Vital signs included parameters such as heart rate, blood pressure, temperature, and respiratory rate. An abnormal vital signs and ECG findings that was judged by the investigator to be clinically significant was reported an AE. TEAEs were defined as events present at baseline that worsened in intensity after administration of MEDI-551, or events absent at baseline that emerged after administration of MEDI-551, for the period extending to 90 days after the end of study treatment.
Time frame: From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant)
Number of Participants Who Developed Detectable MEDI-551 Anti-drug Antibodies (ADA)
A participant was considered ADA-positive across the study if they had a positive reading (titer of 50 or higher) at any time point during the study.
Time frame: 7 days before the start of Cycle 1, Day 1 of each subsequent Cycle, EOT, and post EOT on Days 30, 60, 90 and 270 (up to 36 months from the randomization of last participant)
Mean Serum Concentration of MEDI-551
The mean serum concentration of MEDI-551 were observed.
Time frame: Cycle 1 Day -7 Post dose, pre-dose and postdose on Day 1, post-dose on Days 4, 8, 15 of Cycle 1, pre-dose and postdose on Day 1 of Cycle 2 and Cycle 3
Half-life (T1/2) of MEDI-551
Terminal elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the serum.
Time frame: Cycle 1 and EOT (Day 21 of Cycle 3 [each cycle of 21 days] or earlier cycles if treatment stopped before Cycle 3)
The study was conducted from 27Feb2012 to 17Jun2016.
| Milestone | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|---|
| Started | 80 | 52 | 55 |
| Completed | 0 | 0 | 1 |
| Not completed | 80 | 52 | 54 |
| Withdrew: Lost to follow-up | 3 | 0 | 1 |
| Withdrew: Withdrawal by subject | 8 | 3 | 0 |
| Withdrew: Death | 24 | 22 | 18 |
| Withdrew: Other | 45 | 27 | 35 |
Objective Response Rate is defined as the proportion of participants with a best response of complete response (CR) or partial response (PR) according to the International Working Group criteria. CR is defined as disappearance of all evidence of disease. PR is defined as 50 percent (%) decrease in the sum of the product of the perpendicular diameters (SPD) of up to 6 largest dominant nodal masses and greater than or equal to (\>=) 50% decrease in SPD of spleen/liver nodules.
| Percentage of participants | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|---|
| Objective Response Rate (ORR) | 47.5 (36.2 to 59.0) | 46.2 (32.2 to 60.5) | 43.6 (30.3 to 57.7) |
Progression-free survival (PFS) is defined as the time from randomization until the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first according to the International Working Group criteria. PD is defined as appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \>50% increase from nadir in the SPD of any previous lesions. PFS (months) = (Date of PD/death or censoring - Date of randomization + 1) / (365.25/12).
| months | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|---|
| Progression-Free Survival (PFS) | 6.1 (0.0 to 39.2) | 6.6 (0.0 to 31.3) | 7.7 (0 to 14.8) |
Event-Free Survival (EFS) is defined as the time from randomization until the first documentation of EFS events which include PD, initiation of alternative antitumor treatment or death due to any cause, whichever occurs first according to the International Working Group criteria. PD is defined as appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \>50% increase from nadir in the SPD of any previous lesions. EFS (months) = (Date of EFS or censoring - Date of randomization + 1) / (365.25/12).
| months | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|---|
| Event-Free Survival (EFS) | 4.7 (0.0 to 39.2) | 4.2 (0.0 to 31.3) | 5.9 (0.0 to 14.8) |
Overall survival is defined as the time from randomization until death due to any cause according to the International Working Group criteria. OS (months) = (Date of death or censoring - Date of randomization + 1) / (365.25/12).
| months | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|---|
| Overall Survival (OS) | NA (15.6 to NA) | NA (14.2 to NA) | 23.0 (12.8 to NA) |
Time to Progression (TTP) is defined as the time from randomization until the first documentation of PD according to the International Working Group criteria. PD is defined as appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \>50% increase from nadir in the SPD of any previous lesions. TTP (months) = (Date of PD or censoring - Date of randomization + 1) / (365.25/12).
| months | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|---|
| Time to Progression (TTP) | 4.9 (0.0 to 11.1) | 4.2 (0.0 to 31.3) | 5.9 (0.0 to 14.0) |
Time to response (TTR) is defined as the time from randomization until the first documentation of disease response according to the International Working Group criteria. Only participants who have achieved objective response (confirmed CR or confirmed PR) assessed by investigator were evaluated for TTR. CR is defined as disappearance of all evidence of disease. PR is defined as 50% decrease in the SPD of up to 6 largest dominant nodal masses and \>= 50% decrease in SPD of spleen/liver nodules. TTR (months) = (Date of first disease response - Date of randomization + 1) / (365.25/12).
| months | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|---|
| Time to Response (TTR) | 1.7 (0.9 to 3.8) | 2.3 (1.5 to 3.4) | 2.3 (1.6 to 6.0) |
Duration of Response (DR) is defined as time from start of first documented objective response (confirmed CR or confirmed PR) to first documented PD according to the International Working Group criteria. CR is defined as disappearance of all evidence of disease. PR is defined as 50% decrease in the SPD of up to 6 largest dominant nodal masses and \>= 50% decrease in SPD of spleen/liver nodules. PD: appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \> 50% increase from nadir in the SPD of any previous lesions. Only participants who have achieved objective response assessed by investigator were evaluated. DR calculated as (months) = (Date of PD or censoring - Date of first disease response + 1)/ (365.25/12).
| months | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|---|
| Duration of Response (DR) | NA (4.9 to NA) | 7.1 (4.1 to NA) | 7.9 (4.6 to 12.2) |
The best overall response was calculated, based upon the disease assessments recorded during the study visits, and summarized with the number of participants for the following categories: CR, PR, stable disease (SD), PD, and unknown. Responses were assessed according to the International Working Group criteria. CR: disappearance of all evidence of disease; PR: 50% decrease in the SPD of up to 6 largest dominant nodal masses and \>= 50% decrease in SPD of spleen/liver nodules; PD: appearance of any new lesions or \>= 50% increase in SPD of more than one node or \>= 50% increase in longest diameter of a previously identified node or \>50% increase from nadir in the SPD of any previous lesions; SD: failure to attain CR/PR or PD.
| Participants | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|---|
| COMPLETE RESPONSE (CR) | 20 (16.0 to 35.9) | 6 (4.4 to 23.4) | 12 (11.8 to 35.0) |
| PARTIAL RESPONSE (PR) | 18 | 18 | 12 |
| STABLE DISEASE (SD) | 17 | 12 | 14 |
| PROGRESSIVE DISEASE (PD) | 5 | 5 | 5 |
| UNKNOWN | 20 | 11 | 12 |
Acceptable dose for MEDI-551 was evaluated based on the benefit-risk analysis.
| milligram per kilogram (mg/kg) | MEDI-551 |
|---|---|
| Acceptable Dose of MEDI-551 | 4 |
An Adverse Event (AE) is any unfavourable and unintended signs, symptoms, or diseases temporally associated with use of study drug, whether or not considered related to study drug. Serious adverse event (SAE) is any AE that resulted in death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, life-threatening, a congenital anomaly/birth defect, or an important medical event. TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug, up to 90 days after the end of treatment (EOT).
| Participants | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|---|
| TEAEs | 78 | 51 | 52 |
| TESAEs | 33 | 25 | 27 |
An abnormal laboratory finding that was judged by the investigator to be clinically significant was reported as an AE. TEAEs were defined as events present at baseline that worsened in intensity after administration of MEDI-551, or events absent at baseline that emerged after administration of MEDI-551, for the period extending to 90 days after the end of study treatment (EOT).
| Participants | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|---|
| Anaemia | 47 | 32 | 33 |
| Febrile neutropenia | 16 | 9 | 12 |
| Granulocytopenia | 3 | 0 | 2 |
| Leukopenia | 9 | 6 | 10 |
| Lymphopenia | 4 | 2 | 3 |
| Neutropenia | 30 | 15 | 20 |
| Pancytopenia | 2 | 0 | 3 |
| Thromobocytopenia | 49 | 24 | 29 |
| Activated partial thromboplastin time prolonged | 0 | 2 | 0 |
| Blood immunoglobulin g decreased | 0 | 1 | 0 |
| Blood immunoglobulin m decreased | 0 | 1 | 0 |
| Haemoglobin decreased | 0 | 1 | 0 |
| Immunoglobulins decreased | 0 | 1 | 0 |
| Lymphocyte count decreased | 9 | 4 | 3 |
| Neutrophil count decreased | 7 | 6 | 8 |
| Platelet count decreased | 12 | 8 | 10 |
| Platelet count increased | 0 | 1 | 0 |
| White blood cell count decreased | 6 | 5 | 6 |
An abnormal laboratory findings that was judged by the investigator to be clinically significant was reported as an AE. TEAEs were defined as events present at baseline that worsened in intensity after administration of MEDI-551, or events absent at baseline that emerged after administration of MEDI-551, for the period extending to 90 days after the end of study treatment.
| Participants | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|---|
| Hyperbilirubinaemia | 1 | 0 | 0 |
| Hypernatraemia | 3 | 1 | 1 |
| Hyperphosphataemia | 0 | 0 | 2 |
| Hypertriglyerideaemia | 1 | 0 | 0 |
| Hyperuricaemia | 5 | 4 | 1 |
| Hypoalbuminaemia | 3 | 4 | 3 |
| Hypocalcaemia | 11 | 6 | 7 |
| Hypoglycaemia | 1 | 1 | 1 |
| Hypokalaemia | 24 | 13 | 14 |
| Hypomagnesaemia | 17 | 6 | 11 |
| Hyponatraemia | 8 | 2 | 2 |
| Hypophosphataemia | 4 | 3 | 3 |
| Hypoproteinaemia | 0 | 0 | 1 |
| Alanine aminotransferase increased | 7 | 2 | 4 |
| Aspartate aminotransferase increased | 5 | 2 | 6 |
| Blood alkaline phosphatase increased | 2 | 0 | 1 |
| Blood bicarbonate decreased | 1 | 0 | 0 |
| Blood bilirubin increased | 1 | 1 | 1 |
| Blood chloride increased | 0 | 1 | 0 |
| Blood creatinine increased | 10 | 5 | 7 |
| Blood lactate dehydrogenase increased | 2 | 1 | 1 |
| Blood magnesium decreased | 2 | 0 | 0 |
| Blood potassium decreased | 2 | 0 | 0 |
| Blood uric acid decreased | 0 | 1 | 0 |
| Blood uric acid increased | 1 | 1 | 0 |
| Gamma-glutamyltransferase increased | 9 | 3 | 3 |
| Hepatic enzyme increased | 1 | 0 | 1 |
| Protein total decreased | 0 | 1 | 1 |
| Transaminases increased | 1 | 2 | 0 |
| Dysuria | 2 | 1 | 3 |
| Hematuria | 2 | 3 | 0 |
| Glucose urine present | 0 | 1 | 1 |
| Proteinuria | 0 | 1 | 1 |
| Urine sodium increased | 0 | 0 | 1 |
| Calcium deficiency | 0 | 0 | 1 |
| Electrolyte imbalance | 2 | 0 | 0 |
| Hypercalcaemia | 2 | 1 | 0 |
| Hyperglycaemia | 12 | 9 | 2 |
| Hyperkalaemia | 2 | 2 | 1 |
| Hypermagnesaemia | 3 | 2 | 0 |
Vital signs included parameters such as heart rate, blood pressure, temperature, and respiratory rate. An abnormal vital signs and ECG findings that was judged by the investigator to be clinically significant was reported an AE. TEAEs were defined as events present at baseline that worsened in intensity after administration of MEDI-551, or events absent at baseline that emerged after administration of MEDI-551, for the period extending to 90 days after the end of study treatment.
| Participants | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|---|
| Arrhythmia | 0 | 0 | 2 |
| Atrial fibrillation | 1 | 1 | 2 |
| Bradycardia | 3 | 1 | 2 |
| Extrasystoles | 0 | 1 | 0 |
| Palpitations | 2 | 1 | 0 |
| Sinus arrhythmia | 0 | 0 | 1 |
| Sinus bradycardia | 1 | 2 | 1 |
| Systolic dysfunction | 0 | 0 | 1 |
| Tachycardia | 3 | 1 | 2 |
| Pyrexia | 17 | 14 | 11 |
| Blood pressure increased | 0 | 0 | 1 |
| Carbon dioxide decreased | 1 | 0 | 0 |
| Electrocardiogram abnormal | 0 | 0 | 1 |
| Electrocardiogram QT prolonged | 0 | 2 | 2 |
| Heart rate irregular | 1 | 0 | 0 |
| Weight decreased | 0 | 1 | 1 |
| Weight increased | 1 | 0 | 1 |
| Dyspnoea | 11 | 7 | 8 |
| Dyspnoea exertional | 0 | 3 | 1 |
| Hypertension | 5 | 2 | 3 |
| Hypotension | 10 | 4 | 8 |
A participant was considered ADA-positive across the study if they had a positive reading (titer of 50 or higher) at any time point during the study.
| Participants | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|
| Number of Participants Who Developed Detectable MEDI-551 Anti-drug Antibodies (ADA) | 1 | 0 |
The mean serum concentration of MEDI-551 were observed.
| mcg/mL | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|
| Cycle 1 Day-7 Post Dose | 47.0 ± 23.7 | 83.8 ± 21.9 |
| Cycle 1 Day 1 Pre Dose | 16.7 ± 5.81 | 33.1 ± 16.3 |
| Cycle 1 Day 1 Post Dose | 64.8 ± 26.4 | 116 ± 41.3 |
| Cycle 1 Day 4 | 38.8 ± 14.6 | 71.9 ± 23.0 |
| Cycle 1 Day 8 | 30.6 ± 9.69 | 69.3 ± 25.1 |
| Cycle 1 Day 15 | 19.4 ± 6.19 | 44.7 ± 25.0 |
| Cycle 2 Day 1 Pre Dose | 15.0 ± 5.45 | 30.9 ± 14.3 |
| Cycle 2 Day 1 Post Dose | 52.3 ± 18.7 | 112 ± 32.6 |
| Cycle 3 Day 1 Pre Dose | 14.0 ± 6.50 | 36.4 ± 18.7 |
| Cycle 3 Day 1 Post Dose | 52.4 ± 16.9 | 116 ± 30.9 |
Terminal elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the serum.
| Day | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|
| Cycle 1 | 14.4 ± 5.09 | 16.5 ± 10.5 |
| End of Treatment | 18.9 ± 4.34 | 20.2 ± 5.73 |
Collected over From treatment administration (Day 1) to 90 days after the end of study treatment (up to approximately 36 months from the randomization of last participant). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab+ ICE/DHAP | — | 33/79 (41.8%) | 78/79 (98.7%) |
| MEDI-551 2 mg/kg + ICE/DHAP | — | 25/52 (48.1%) | 49/52 (94.2%) |
| MEDI-551 4 mg/kg + ICE/DHAP | — | 27/54 (50%) | 52/54 (96.3%) |
| Event | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 11/79 | 8/52 | 9/54 |
| SepsisInfections and infestations | 3/79 | 1/52 | 4/54 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/79 | 0/52 | 1/54 |
| Acute kidney injuryRenal and urinary disorders | 3/79 | 3/52 | 2/54 |
| NeutropeniaBlood and lymphatic system disorders | 4/79 | 1/52 | 3/54 |
| PyrexiaGeneral disorders | 1/79 | 2/52 | 2/54 |
| Tumour lysis syndromeMetabolism and nutrition disorders | 0/79 | 2/52 | 1/54 |
| SyncopeNervous system disorders | 0/79 | 2/52 | 0/54 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/79 | 2/52 | 2/54 |
| PneumoniaInfections and infestations | 3/79 | 0/52 | 1/54 |
| Event | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 47/79 | 32/52 | 33/54 |
| ThrombocytopeniaBlood and lymphatic system disorders | 47/79 | 24/52 | 28/54 |
| NauseaGastrointestinal disorders | 43/79 | 23/52 | 25/54 |
| FatigueGeneral disorders | 22/79 | 20/52 | 15/54 |
| NeutropeniaBlood and lymphatic system disorders | 27/79 | 15/52 | 18/54 |
| ConstipationGastrointestinal disorders | 23/79 | 17/52 | 18/54 |
| VomitingGastrointestinal disorders | 26/79 | 14/52 | 14/54 |
| HypokalaemiaMetabolism and nutrition disorders | 24/79 | 13/52 | 14/54 |
| DiarrhoeaGastrointestinal disorders | 19/79 | 15/52 | 13/54 |
| AstheniaGeneral disorders | 9/79 | 12/52 | 11/54 |
Intent-To-Treat population included all participants who were randomized into the study.
| Age, Continuous(YEARS) | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP | TOTAL |
|---|---|---|---|---|
| Mean | 56.4 ± 12.3 | 56.9 ± 11.4 | 55.9 ± 11.6 | 56.4 ± 11.8 |
| Age, Customized(Participants) | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP | TOTAL |
|---|---|---|---|---|
| < 65 YEARS | 60 | 35 | 43 | 138 |
| >= 65 YEARS | 20 | 17 | 12 | 49 |
| Sex: Female, Male(Participants) | Rituximab+ ICE/DHAP | MEDI-551 2 mg/kg + ICE/DHAP | MEDI-551 4 mg/kg + ICE/DHAP | TOTAL |
|---|---|---|---|---|
| Female | 35 | 19 | 24 | 78 |
| Male | 45 | 33 | 31 | 109 |
Ran from Feb 2012 to primary completion in Jul 2016, 52 months.
Results were first posted in Mar 2018, 1 year 8 months after primary completion. A results delay was requested in Jun 2017.
Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 52 months is above that.
Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inebilizumab
Lymphoma, Large B-Cell, Diffuse →